Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03896971|
Recruitment Status : Completed
First Posted : April 1, 2019
Last Update Posted : September 29, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
To the investigator's Knowledge this is the first study that will assess Treatment with thrombopoietin Mimetic plus immunosuppressiveTherapy in Egyptian Patients with Aplastic Anaemia.
Aim of the work :
- To evaluate the efficacy, tolerability and toxicity of the combination of thrombopoietin mimetic and immunosuppressive therapy in Egyptian patients with AA.
- To study the influence of this combination on patients' quality of life.
- To access evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome , acute leukemia or development of fibrosis
|Condition or disease||Intervention/treatment||Phase|
|Aplastic Anemia||Drug: Combination of thrombopoietin mimetic and cyclosporin A||Phase 4|
Aplastic anemia (AA) is a bone marrow failure syndrome that, although benign in nature, it influences patients' quality of life and carries poor prognosis.The pathophysiological basis of development of acquired AA include immune-mediated attack, inherent hematopoietic stem cell insufficiency and telomere defects. Bone marrow transplantation (BMT) is the only curative treatment for AA. Unfortunately it is unavailable for many patients due to lack of matched donors furthermore others are ineligible for BMT due to old age or co-morbid conditions. Immunosuppressive therapy was the mainstay of treatment for AA for many years, however many patients developed resistance or refractoriness. Immunosuppressive therapy was in the form of antithymocyte globulin (ATG) which gave hematologic response in nearly 50% of patients , adding cyclosporin A increases this response to 70%. Why some patients became resistant to immunosuppressive therapy ? The answer is not known.
Thrombopoietin mimetic (Eltrombopag) was firstly FDA approved for treatment of immune thrombocytopenic purpura. Numerous clinical trials proved the efficacy of anthropometric mimetic in patients with refractory severe AA, leading to its FDA approval for this group of patients. Some researchers proven the efficacy of thrombopoietin mimetic in patients with moderate aplastic anemia.
This study aimed to asses the combination of thrombopoietin mimetic and immunosuppressive therapy in patients with AA.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||66 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Two groups of patients will be included one group will be treated with thrombopoietin mimetic and immunosuppressive therapy , another matched group treated with immunosuppressive therapy alone and enrolled retrospectively|
|Masking:||None (Open Label)|
|Official Title:||Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia|
|Actual Study Start Date :||November 15, 2019|
|Actual Primary Completion Date :||December 1, 2020|
|Actual Study Completion Date :||June 1, 2021|
Experimental: Thrombopoietin mimetic plus immunosuppressive therapy
The intervention group will be given cyclosporin A plus thrombopoietin (TPO) mimetic starting with 50 mg orally daily that would be increased or decreased according to response, for 3-months. Patients will be kept on weekly follow up visits and assessed by peripheral hemogram .
Drug: Combination of thrombopoietin mimetic and cyclosporin A
This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
Other Name: Combination of Eltrombopag plus cyclosporin A
No Intervention: Immunosuppressive therapy
A comparative group will be collected retrospectively and treated with cyclosporin A alone as standard.
- Number of patients with hematologjc response [ Time Frame: 2-3months ]
- Platelet number ( time frame(2-3 months) : Increase plt count 20, 000 or more from baseline or independence of platelet transfusion for 2 months
- Hemoglobin percent (time frame (2-3 months): increase Hb by 1.5 g/dl from baseline or reduction 4 units of packed red blood cell transfusions for 2- months C) Absolute neutrophilic count response (time frame (2-3 months): increase absolute neutrophil count by 500 per microliter from baseline.
d) Bone marrow cellularity (time frame (2-3 months): increase bone marrow cellularity from baseline
- Number of patients with one of the following [ Time Frame: 2-3months ]
- Toxicity: development of toxicity leading to cessation of treatment
- Evolution: evolution to paroxysmal nocturnal hemoglobinuria , myelodysplastic syndrome or acute leukemia
- Bleeding and cytopenias that met the criteria for severe aplastic anemia and require transfusions
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||16 Years to 65 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Eligible for treatment with thrombopoietin mimetic.
- Willing to participate in the study and signed informed consent.
- Unavailability of BMT -
- Patient with inherited aplastic anemia
- Underlying immune deficiency
- Contra indication to cyclosporin A
- Endstage hepatic or renal disease
- Pregnancy and lactation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03896971
|Assiut university hospital Internal Medicine Department Hematology and BMT Unit|
|Assiut, Egypt, 71515|
|Study Director:||Safinaz Hussien, MD||Assiut University|
|Principal Investigator:||Sawsan A Abdelaal, M.B.B.Ch||Assiut University|
|Responsible Party:||Safaa AA Khaled, Associate professor, Assiut University|
|Other Study ID Numbers:||
|First Posted:||April 1, 2019 Key Record Dates|
|Last Update Posted:||September 29, 2021|
|Last Verified:||September 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Bone Marrow Failure Disorders
Bone Marrow Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs